List view / Grid view
In this Q&A, Debiopharm’s Principal Scientist Dr Luke Piggott defines the critical requirement of biomarkers for identifying rare diseases. He illuminates how AI-enhanced approaches are accelerating the drug discovery process, particularly regarding clinical trial enrolment, and the breakthroughs he hopes to see in the future.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
9 April 2024 | By Eurofins Discovery
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
Tune in to this episode where we discuss the opportunities CRISPR/Cas technology offers to revolutionise drug discovery.
A highly specific blood test can differentiate between patients with sarcoidosis and other respiratory conditions, like TB or lung cancer.
22 February 2024 | By Dr. Reece Gardner
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times.
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
Using CRISPRa to activate genes in readily accessible cells provides an effective and accurate diagnosis of genetic diseases.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Tips and tricks for fully leveraging Advanced Flow Cytometry.
